Clinical-stage biopharmaceutical company, Autolus, and provider of products and services for biomedical research and cellular therapy, Miltenyi Biotec, have signed a strategic long-term supply agreement.
Partnership
This agreement covers the supply and support of Miltenyi Biotec Prodigy platform for the manufacture of Autolus programmed T cell therapies.
"We are delighted to announce our strategic relationship with Miltenyi Biotec, a pioneer in design and engineering of equipment and reagents that support production of cell therapies," said Dr Christian Itin, CEO of Autolus. "This agreement builds on the longstanding collaboration between our companies and leverages our respective leadership positions in programmed T cell therapies, process design, engineering and automation."
Stefan Miltenyi, president and CEO at Miltenyi Biotec, added: "Autolus is a leader in the development of programmed T cell therapies. We are therefore delighted that Autolus has chosen our Prodigy platform for the manufacture of its clinical-stage portfolio and we look forward to further demonstrating its utility in the commercial manufacture of advanced T cell therapies."